Analyst Viewpoint
Rise in prevalence of mental disorders is propelling the insomnia market size. Increase in work related stress is leading to surge in cases of sleep disorders across age groups globally. Smart wearable medical devices integrated with smartphone applications are gaining popularity for sleep management.
Growth in geriatric population is driving the insomnia market expansion. Prominent players operating in the global insomnia industry are investing in the R&D of novel drug formulations to combat sleep irregularity and anxiety. Manufacturers are also working on innovating drugs that are effective in smaller dosages to reduce the risk of addiction.
Insomnia is the most common sleep disorder, affecting around 35% of the population worldwide. A minimum of seven hours of sleep is required for adults to lead a healthy lifestyle. However, a third of the global population gets less than required, which is affecting their long-term physical and mental health.
Insomnia therapeutics are commonly available as low dose sedating anti-depressants and nonbenzodiazepines. The global insomnia industry is heavily fragmented with several high barrier points to entry such as product efficacy, innovation, and cost. In recent times, the rise in stress levels is leading to high incidences of mental disorders, which is fueling the insomnia market revenue.
The current socio-economic climate coupled with work-life stress is boosting the prevalence of mental disorders across demographics. Anxiety, depression, and other mental illnesses are linked to several sleep disorders such as insomnia and obstructive sleep apnea. Symptoms of insomnia, including wakefulness and anxiety, may seem benign but can lead to flawed judgment, accidents, and even death.
According to American Academy of Sleep Medicine, mental health issues and substance abuse are prominent causes of sleep disorders in 3% of the global adult population. Over one-fifth of the population suffers from stress-related loss of sleep each year. In the U.S., US$ 94.9 Bn is spent each year on sleep disorder care and therapeutics.
Chronic and acute insomnia is evident in the majority of the elderly population worldwide. Older people usually suffer from an inability to maintain sleep. Management of sleep disorders in such patients is complex and requires careful evaluation of underlying medical conditions and ongoing treatments. Hence, rise in geriatric population is fueling the insomnia market progress.
In male patients, lack of sleep is co-related with morbidity, morality, and enhanced risk of nursing home placements. A range of therapeutic care offerings exist for the elderly. R&D of new drugs is expected to spur the insomnia market growth in the near future. In December 2022, Zydus Lifesciences received final approval from the U.S. Food and Drug Administration to market Triazolam tablets 0.125 mg and 0.25 mg. for the treatment of insomnia on a short-term basis.
According to the latest insomnia market analysis, North America held largest share in 2022. Surge in cases of sleeping disorders and increase in healthcare expenditure are augmenting the market dynamics of the region. According to the American Sleep Association, about 70 million people in the U.S. suffer from sleeping disorders. Men constitute a significant proportion of this group.
According to the latest insomnia industry forecast, the industry in Asia Pacific is projected to grow at a steady pace from 2023 to 2031. High-stress work culture is propelling the insomnia market statistics in the region.
According to the recent insomnia market trends, prominent manufacturers are investing heavily in the development of next-gen insomnia drugs to combat nighttime wakefulness. They are developing smart and wearable sleep-inducing devices. These devices are integrated with mobile applications and designed specifically to enable patients to sleep faster for a relatively healthy amount of time.
Paratek Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., Teva Pharmaceutical Industries Limited, Vanda Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Sanofi S.A, Merck & Co., Inc., and Viatris Inc. are key companies operating in this market.
These companies have been profiled in the insomnia market report based on various parameters such as company overview, product portfolio, business strategies, financial overview, and business segments.
| Attribute | Detail |
|---|---|
| Market Value in 2022 (Base Year) | US$ 3.8 Bn |
| Market Forecast Value in 2031 | US$ 6.4 Bn |
| Growth Rate (CAGR) | 6.0% |
| Forecast Period | 2023 to 2031 |
| Historical Data Available for | 2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | Qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Regions Covered |
|
| Countries Covered |
|
| Market Segmentation |
|
| Companies Profiled |
|
| Customization Scope | Available upon Request |
| Pricing | Available upon Request |
It was valued at US$ 3.8 Bn in 2022
It is projected to grow at a CAGR of 6.0% from 2023 to 2031
Rise in prevalence of mental disorders and surge in geriatric population
The benzodiazepines segment held the largest share in 2022
North America dominated the global landscape in 2022
Paratek Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., Teva Pharmaceutical Industries Limited, Vanda Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Sanofi S.A, Merck & Co., Inc., and Viatris Inc.
1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Insomnia Market
4. Market Overview
4.1. Market Segmentation
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Insomnia Market Analysis and Forecasts, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Disease Prevalence & Incidence Rate Globally with Key Countries
5.3. COVID-19 Pandemic Impact on Industry
6. Insomnia Market Analysis and Forecast, by Treatment Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment Type, 2017–2031
6.3.1. Benzodiazepines
6.3.2. Nonbenzodiazepines
6.3.3. Antidepressants
6.3.4. Orexin Antagonist
6.3.5. Melatonin Antagonist
6.3.6. Devices
6.3.7. Others
6.4. Market Attractiveness, by Treatment Type
7. Global Insomnia Market Analysis and Forecast, by Sales Channel
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Sales Channel, 2017–2031
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies and Drug Stores
7.3.3. Online Pharmacies
7.4. Market Attractiveness, by Sales Channel
8. Global Insomnia Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2017–2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
9. North America Insomnia Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Treatment Type, 2017–2031
9.2.1. Benzodiazepines
9.2.2. Nonbenzodiazepines
9.2.3. Antidepressants
9.2.4. Orexin Antagonist
9.2.5. Melatonin Antagonist
9.2.6. Devices
9.2.7. Others
9.3. Market Value Forecast, by Sales Channel, 2017–2031
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies and Drug Stores
9.3.3. Online Pharmacies
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Treatment Type
9.5.2. By Sales Channel
9.5.3. By Country
10. Europe Insomnia Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Treatment Type, 2017–2031
10.2.1. Benzodiazepines
10.2.2. Nonbenzodiazepines
10.2.3. Antidepressants
10.2.4. Orexin Antagonist
10.2.5. Melatonin Antagonist
10.2.6. Devices
10.2.7. Others
10.3. Market Value Forecast, by Sales Channel, 2017–2031
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies and Drug Stores
10.3.3. Online Pharmacies
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Treatment Type
10.5.2. By Sales Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Insomnia Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment Type, 2017–2031
11.2.1. Benzodiazepines
11.2.2. Nonbenzodiazepines
11.2.3. Antidepressants
11.2.4. Orexin Antagonist
11.2.5. Melatonin Antagonist
11.2.6. Devices
11.2.7. Others
11.3. Market Value Forecast, by Sales Channel, 2017–2031
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies and Drug Stores
11.3.3. Online Pharmacies
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Treatment Type
11.5.2. By Sales Channel
11.5.3. By Country/Sub-region
12. Latin America Insomnia Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment Type, 2017–2031
12.2.1. Benzodiazepines
12.2.2. Nonbenzodiazepines
12.2.3. Antidepressants
12.2.4. Orexin Antagonist
12.2.5. Melatonin Antagonist
12.2.6. Devices
12.2.7. Others
12.3. Market Value Forecast, by Sales Channel, 2017–2031
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies and Drug Stores
12.3.3. Online Pharmacies
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Treatment Type
12.5.2. By Sales Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Insomnia Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment Type, 2017–2031
13.2.1. Benzodiazepines
13.2.2. Nonbenzodiazepines
13.2.3. Antidepressants
13.2.4. Orexin Antagonist
13.2.5. Melatonin Antagonist
13.2.6. Devices
13.2.7. Others
13.3. Market Value Forecast, by Sales Channel, 2017–2031
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies and Drug Stores
13.3.3. Online Pharmacies
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Treatment Type
13.5.2. By Sales Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. Paratek Pharmaceuticals, Inc.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Treatment Type Portfolio
14.3.1.3. Financial Overview
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Sumitomo Dainippon Pharma Co., Ltd.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Treatment Type Portfolio
14.3.2.3. Financial Overview
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. Teva Pharmaceutical Industries Limited
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Treatment Type Portfolio
14.3.3.3. Financial Overview
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Vanda Pharmaceuticals Inc.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Treatment Type Portfolio
14.3.4.3. Financial Overview
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Takeda Pharmaceutical Company Limited
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Treatment Type Portfolio
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Pfizer Inc.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Treatment Type Portfolio
14.3.6.3. Financial Overview
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. Sanofi S.A
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Treatment Type Portfolio
14.3.7.3. Financial Overview
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Merck & Co., Inc.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Treatment Type Portfolio
14.3.8.3. Financial Overview
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. Viatris Inc.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Treatment Type Portfolio
14.3.9.3. Financial Overview
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
List of Tables
Table 01: Global Insomnia Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 02: Global Insomnia Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2031
Table 03: Global Insomnia Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 04: North America Insomnia Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 05: North America Insomnia Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2031
Table 06: North America Insomnia Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 07: Europe Insomnia Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 08: Europe Insomnia Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2031
Table 09: Europe Insomnia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Asia Pacific Insomnia Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 11: Asia Pacific Insomnia Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2031
Table 12: Asia Pacific Insomnia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 13: Latin America Insomnia Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 14: Latin America Insomnia Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2031
Table 15: Latin America Insomnia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 16: Middle East & Africa Insomnia Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 17: Middle East & Africa Insomnia Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2031
Table 18: Middle East & Africa Insomnia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
List of Figures
Figure 01: Global Insomnia Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Insomnia Market Value Share Analysis, by Treatment Type 2022 and 2031
Figure 03: Global Insomnia Market Attractiveness Analysis, by Treatment Type, 2017–2031
Figure 04: Global Insomnia Market Value Share Analysis, by Sales Channel, 2022 and 2031
Figure 05: Global Insomnia Market Attractiveness Analysis, by Sales Channel, 2017–2031
Figure 06: Global Insomnia Market Value Share Analysis, by Region, 2022 and 2031
Figure 07: Global Insomnia Market Attractiveness Analysis, by Region, 2017–2031
Figure 08: North America Insomnia Market Value (US$ Mn) Forecast, 2017–2031
Figure 09: North America Insomnia Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 10: North America Insomnia Market Attractiveness Analysis, by Treatment Type, 2017–2031
Figure 11: North America Insomnia Market Value Share Analysis, by Sales Channel, 2022 and 2031
Figure 12: North America Insomnia Market Attractiveness Analysis, by Sales Channel, 2017–2031
Figure 13: North America Insomnia Market Value Share Analysis, by Country, 2022 and 2031
Figure 14: North America Insomnia Market Attractiveness Analysis, by Country, 2017–2031
Figure 15: Europe Insomnia Market Value (US$ Mn) Forecast, 2017–2031
Figure 16: Europe Insomnia Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 17: Europe Insomnia Market Attractiveness Analysis, by Treatment Type, 2017–2031
Figure 18: Europe Insomnia Market Value Share Analysis, by Sales Channel, 2022 and 2031
Figure 19: Europe Insomnia Market Attractiveness Analysis, by Sales Channel, 2017–2031
Figure 20: Europe Insomnia Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 21: Europe Insomnia Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 22: Asia Pacific Insomnia Market Value (US$ Mn) Forecast, 2017–2031
Figure 23: Asia Pacific Insomnia Market Value Share Analysis, by Treatment Type 2022 and 2031
Figure 24: Asia Pacific Insomnia Market Attractiveness Analysis, by Treatment Type, 2017–2031
Figure 25: Asia Pacific Insomnia Market Value Share Analysis, by Sales Channel, 2022 and 2031
Figure 26: Asia Pacific Insomnia Market Attractiveness Analysis, by Sales Channel, 2017–2031
Figure 27: Asia Pacific Insomnia Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 28: Asia Pacific Insomnia Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 29: Latin America Insomnia Market Value (US$ Mn) Forecast, 2017–2031
Figure 30: Latin America Insomnia Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 31: Latin America Insomnia Market Attractiveness Analysis, by Treatment Type, 2017–2031
Figure 32: Latin America Insomnia Market Value Share Analysis, by Sales Channel, 2022 and 2031
Figure 33: Latin America Insomnia Market Attractiveness Analysis, by Sales Channel, 2017–2031
Figure 34: Latin America Insomnia Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 35: Latin America Insomnia Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 36: Middle East & Africa Insomnia Market Value (US$ Mn) Forecast, 2017–2031
Figure 37: Middle East & Africa Insomnia Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 38: Middle East & Africa Insomnia Market Attractiveness Analysis, by Treatment Type, 2017–2031
Figure 39: Middle East & Africa Insomnia Market Value Share Analysis, by Sales Channel, 2022 and 2031
Figure 40: Middle East & Africa Insomnia Market Attractiveness Analysis, by Sales Channel, 2017–2031
Figure 41: Middle East & Africa Insomnia Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 42: Middle East & Africa Insomnia Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 43: Global Insomnia Market Share Analysis, by Company, 2022
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Insomnia Market
